A Comprehensive Analysis of Axatilimab in Patients with Chronic Graft-Versus-Host Disease and Related Bronchiolitis Obliterans Syndrome: Integrated Analysis from 2 Clinical Studies

Key Points

• Axatilimab showed a significant impact on chronic graft-versus-host disease outcomes, suggesting improved patient management.
• Patients experienced notable relief from bronchiolitis obliterans syndrome, with measurable improvements in respiratory function.
• Observational analysis across two clinical studies demonstrated robust immune response metrics in treated patients.
• Findings support the potential of axatilimab as a promising therapeutic intervention in chronic graft-versus-host disease.